Loading...
•
Dec 31, 2023
TG Therapeutics Q4 2023 Earnings Report
TG Therapeutics reported BRIUMVI U.S. net revenue of $39.9 million and a net loss of $14.4 million for the fourth quarter of 2023.
Key Takeaways
TG Therapeutics announced its Q4 and full year 2023 financial results, highlighted by BRIUMVI U.S. net product revenue of $39.9 million for the quarter and $88.8 million for the year. The company's net loss for the quarter was $14.4 million, with a year-end cash position of $217.5 million.
BRIUMVI U.S. net product revenue reached $39.9 million for Q4 2023 and $88.8 million for the full year.
Approximately 3200 BRIUMVI prescriptions have been received since launch.
TG Therapeutics' partner, Neuraxpharm, commenced the launch of BRIUMVI in Europe.
The company anticipates that its cash, cash equivalents, and investment securities, combined with projected revenues from BRIUMVI, will be sufficient to fund planned operations into cash flow positivity.
TG Therapeutics
TG Therapeutics
Forward Guidance
TG Therapeutics provided BRIUMVI U.S. net product revenue target of approximately $220 million to $260 million for the full year 2024 and a full year 2024 target operating expense of approximately $250 million.
Positive Outlook
- BRIUMVI U.S. net product revenue target of approximately $220 million to $260 million for the full year 2024
- Full year 2024 target operating expense of approximately $250 million
- Commence clinical development of subcutaneous BRIUMVI
- Commence a trial evaluating BRIUMVI in an additional autoimmune disease outside of multiple sclerosis (MS)
- Commence a trial evaluating azer-cel in autoimmune disease